Halozyme Therapeutics, Inc.
Price Action
Technical Summary
WEAKENINGHalozyme Therapeutics, Inc. is in a technical downtrend, trading below key resistance levels with a broken trend structure. Relative strength is moderate (RS Rating: 55), indicating performance broadly in line with the market. Earnings growth of 31% provides fundamental context to the price action. A decisive close above the 200-day moving average is required to signal a potential trend reversal.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $69.39 | -0.57% | BELOW |
| 50 SMA | $67.89 | +1.62% | ABOVE |
| 100 SMA | $68.67 | +0.47% | ABOVE |
| 150 SMA | $68.72 | +0.40% | ABOVE |
| 200 SMA | $69.14 | -0.22% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is HALO in an uptrend right now?
HALO has a trend score of 1/4 based on Minervini's Stage Analysis. Currently showing broken structure - 1 of 4 trend criteria are met.
Is HALO overbought or oversold?
HALO's RSI (14) is 48. The stock is in neutral territory, neither overbought nor oversold.
Is HALO outperforming the market?
HALO has a Relative Strength (RS) Rating of 55 out of 99. HALO is performing about average compared to the market.
Where is HALO in its 52-week range?
HALO is trading at $68.99, which is 84% of its 52-week high ($82.22) and 58% above its 52-week low ($51.06).
How volatile is HALO?
HALO has a Beta of 0.61 and 52-week volatility of 31%. It's less volatile than the S&P 500 - generally more stable.